Virtual ACC 2020 | First Results of Evolut in Low-Risk Bicuspid Valves

The initial results of this study presented “virtually” at the American College of Cardiology (ACC) 2020 Scientific Session suggest that patients with severe bicuspid aortic stenosis can be treated with self-expandable valve Evolut.

This is a small study presenting its 30-day outcomes. There is still a long way to go. The rate of all-cause mortality or disabling stroke was 1.3%, while the rate of nondisabling stroke was 3.3%, quite similar to that observed in trials in low-risk patients with normal valve anatomy.

Long-term follow-up will be crucial to know whether transcatheter aortic valve replacement (TAVR) is warranted in patients with such a challenging anatomy, who can undergo conventional surgery perfectly.

This trial featured a particularly select population that specifically excluded very young patients (< 60 years old). Additionally, the rate of pacemaker implantation with TAVR (14.7%) almost tripled the rate reported with conventional surgery (5%).

Original Title: Primary results from the Evolut Low-Risk Bicuspid Study.

Reference: Ramlawi B et al. ACC 2020 virtual.

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.